Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
2(28.6%)
Early Phase 1
1(14.3%)
7Total
Phase 2(4)
Phase 1(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07373301Phase 2Not Yet Recruiting

Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia

Role: lead

NCT00367380Phase 2Completed

Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers

Role: lead

NCT04739917Phase 2Unknown

Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers

Role: lead

NCT01082341Phase 1Completed

Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites

Role: lead

NCT02083068Phase 2Completed

Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax

Role: lead

NCT01083095Early Phase 1Completed

Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers

Role: lead

NCT01081847Phase 1Completed

Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants

Role: lead

All 7 trials loaded